Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desoximetasone + tacrolimus is a topical combination of two active pharmaceutical ingredients used primarily in dermatology. Desoximetasone is a potent synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, acting mainly by binding to the glucocorticoid receptor to modulate gene expression and suppress inflammatory mediators. Tacrolimus is a macrolide immunosuppressant that inhibits calcineurin by binding to FKBP-12, thereby blocking T-lymphocyte activation and cytokine (notably IL-2) transcription. This combination may be used off-label for inflammatory skin conditions such as atopic dermatitis when monotherapy is insufficient or for short-term management of severe disease. Studies have shown that these agents are physically and chemically compatible when mixed in equal parts as ointments[1][4]. Each drug retains its mechanism of action within the mixture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desoximetasone + tacrolimus.